<DOC>
	<DOCNO>NCT01790126</DOCNO>
	<brief_summary>The propose clinical trial study effect 12 month therapy ARN-509 alone , combination LHRH agonist ( LHRHa ) , compare LHRHa alone , men rapidly rise serum PSA prior definitive local therapy prostate cancer . The endpoint select reflect measurable short term effect androgen deprivation therapy ( ADT ) , include quality life several metabolic parameter . In addition , relative effect treatment strategy PSA suppression well testosterone recovery ( subsequent PSA progression ) 12 month therapy evaluate .</brief_summary>
	<brief_title>The Role Highly Selective Androgen Receptor ( AR ) Targeted Therapy Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Key Histologically prove adenocarcinoma prostate Rising PSA prior definitive local therapy ( radical prostatectomy , external beam radiation , brachytherapy ) combination radical prostatectomy radiotherapy curative intent PSA double time le equal 12 month No evidence metastatic disease image whole body bone scan computerize tomography ( CT ) Magnetic Resonance Imaging ( MRI ) abdomen/pelvis within 6 week prior randomization Minimum PSA 1.0 ng/mL prior radical prostatectomy +/ adjuvant salvage radiation ; nadir + 2.0 ng/mL prior RT without prior radical prostatectomy Prior androgen deprivation therapy ( ADT ) allow last dose great ( &gt; ) 6 month prior randomization No prior androgen deprivation therapy ( ADT ) antiandrogen biochemical relapse Serum testosterone &gt; 150 ng/dL study entry No history seizures medical condition may lower seizure threshold Key Use 5alpha reductase antagonist ( i.e . finasteride , dutasteride ) within 6 week prior randomization Use antiandrogen ( e.g . flutamide , nilutamide , bicalutamide ) within 6 week prior randomization Prior bilateral orchiectomy Prior treatment ADT biochemically relapse prostate cancer . Prior ADT neoadjuvant , concurrent , and/or adjuvant treatment follow salvage radiation therapy prostatectomy biochemically relapse disease allow provide last dose ADT great ( &gt; ) 6 month prior randomization Screening serum testosterone level great equal ( â‰¥ ) 150 ng/dL Use systemic steroid equivalent dose prednisone 5 mg/day high randomization Any history seizure medical condition lower seizure threshold</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Men Biochemically Relapsed Hormone Sensitive Prostate Cancer</keyword>
</DOC>